Results
eNauka >
Results >
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
| Title: | Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world | Authors  : | Kapelios, Chris J; ...; Seferovic, Petar M  ; ...; Seferovic, Petar M ; ...; (broj, koautora 617) |
Issue Date: | 2019 | Publication: | EUROPEAN JOURNAL OF HEART FAILURE | ISSN: | 1388-9842 European Journal of Heart Failure Search Idenfier |
Type: | Article | Collation: | vol. 21 br. 11 str. 1383-1397 | DOI: | 10.1002/ejhf.1532 | WoS-ID: | 000497176400011 | Scopus-ID: | 2-s2.0-85067693318 | URI: | https://enauka.gov.rs/handle/123456789/830733 | Project: | Abbott Laboratories Amgen Cardiovascular AstraZeneca Bayer AG Boehringer Ingelheim Boston Scientific Bristol Myers Squibb and Pfizer Alliance Daiichi Sankyo Europe GmbHDaiic |
Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | 21a+M21a+ |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.